|
|
| | Methylenedioxypyrovalerone-d8 Hydrochloride Basic information |
| Product Name: | Methylenedioxypyrovalerone-d8 Hydrochloride | | Synonyms: | MDPV-D8 HCl;Methylenedioxypyrovalerone-d8 Hydrochloride;1-(1,3-Benzodioxol-5-yl)-2-(1-pyrrolidinyl-d8)-;3,4-Methylenedioxypyrovalerone-d8 HCl (MDPV-d8 HCl) solution;3,4-Methylenedioxypyrovalerone-d8 hydrochloride;1-(1,3-benzodioxol-5-yl)-2-(2,2,3,3,4,4,5,5-octadeuteriopyrrolidin-1-yl)pentan-1-one:hydrochloride;3,4-Methylenedioxy Pyrovalerone-d8;3,4-Methylenedioxypyrovalerone-D8.HCl, 1mg/ml in Methanol (as free base) | | CAS: | 1246820-09-6 | | MF: | C16H22ClNO3 | | MW: | 311.80378 | | EINECS: | 200-659-6 | | Product Categories: | Amines;Heterocycles;Intermediates & Fine Chemicals;Isotope Labelled Compounds;Pharmaceuticals | | Mol File: | 1246820-09-6.mol |  |
| | Methylenedioxypyrovalerone-d8 Hydrochloride Chemical Properties |
| Melting point | 227-229C | | Fp | 9℃ | | storage temp. | Hygroscopic, -20°C Freezer, Under Inert Atmosphere | | solubility | DMF: 0.25 mg/ml; DMSO: 0.1 mg/ml; Ethanol: 1 mg/ml; PBS (pH 7.2): 10 mg/ml | | form | A crystalline solid | | Stability: | Hygroscopic | | Major Application | pharmaceutical (small molecule) |
| Hazard Codes | F,T | | Risk Statements | 11-23/24/25-39/23/24/25 | | Safety Statements | 7-16-36/37-45 | | RIDADR | UN1230 - class 3 - PG 2 - Methanol, solution | | WGK Germany | 1 | | Storage Class | 3 - Flammable liquids | | Hazard Classifications | Eye Irrit. 2
Flam. Liq. 2 |
| | Methylenedioxypyrovalerone-d8 Hydrochloride Usage And Synthesis |
| Description | 3,4-Methylenedioxy Pyrovalerone-d8 (hydrochloride) (3,4-MDPV-d8 (hydrochloride)) contains eight deuterium atoms at the 1-pyrrolidinyl position. It is intended for use as an internal standard for the quantification of 3,4-MDPV by GC- or LC-mass spectrometry. Pyrovalerone and its analogs are inhibitors of the transporters for certain monoamine neurotransmitters, including dopamine and norepinephrine, preventing their uptake. 3,4-MDPV is an analog of pyrovalerone which includes the 3,4-methylenedioxy moiety found on 3,4-methylenedioxymethamphetamine, a DEA Schedule I controlled substance. While its physiological, neurological, and toxicological actions have not been characterized, 3,4-MDPV has been reported by the DEA to be abused as a central nervous system stimulant. Its effective dose and chemical interactions are unknown, but it has been used alone and in combination with other stimulating compounds. Products containing 3,4-MDPV have been marketed in Europe and Australia; they have also been seized by law enforcement in several states. 3,4-MDPV and some of its metabolites have recently been characterized by spectroscopic analysis. 3,4-MDPV is to be used in the forensic analysis of samples that may contain this compound. This product, the hydrochloride salt of 3,4-MDPV, has superior solubility in aqueous solvents, compared to the free base . | | Chemical Properties | White Solid | | Uses | Labelled Methylenedioxypyrovalerone (MDPV; Cat. # M304080) as a central nervous system | | Uses | Labelled Methylenedioxypyrovalerone (M304080) as a central nervous system | | References | [1] CATHERINE HéRON Jean J B Jean Costentin. Evidence that pure uptake inhibitors including cocaine interact slowly with the dopamine neuronal carrier[J]. European journal of pharmacology, 1994, 264 3: Pages 391-398. DOI: 10.1016/0014-2999(94)00502-8
[2] De Souza, F.I., Zumiotti, A.V., and Da Silva, C.F. Neuregulins 1-α and 1-β on the regeneration the peripheral nerves[J]. Acta Ortop Bras.
[3] FOLKER WESTPHAL . Mass and NMR spectroscopic characterization of 3,4-methylenedioxypyrovalerone: A designer drug with α-pyrrolidinophenone structure[J]. Forensic science international, 2009, 190 1: Pages 1-8. DOI: 10.1016/j.forsciint.2009.05.001
[4] MARKUS R. MEYER. Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC–MS and LC–high-resolution MS and its detectability in urine by GC–MS[J]. Journal of Mass Spectrometry, 2010, 45 12: 1426-1442. DOI: 10.1002/jms.1859
[5] KINGA FARKAS. [Clinical characteristics of 5 hospitalized 3,4-methylenedioxypyrovalerone (MDPV) users].[J]. Psychiatria Hungarica, 2013, 28 4: 431-439.
[6] SABINA STRANO-ROSSI. Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MPDV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry[J]. Rapid Communications in Mass Spectrometry, 2010, 24 18: 2706-2714. DOI: 10.1002/rcm.4692 |
| | Methylenedioxypyrovalerone-d8 Hydrochloride Preparation Products And Raw materials |
|